Solventum (NYSE:SOLV) Now Covered by Analysts at Rothschild & Co Redburn

Rothschild & Co Redburn assumed coverage on shares of Solventum (NYSE:SOLV) in a research note published on Tuesday morning, MarketBeat Ratings reports. The firm issued a sell rating and a $60.00 target price on the stock.

SOLV has been the topic of a number of other reports. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Wells Fargo & Company raised Solventum to a “hold” rating in a research note on Wednesday, March 18th. KeyCorp raised their price target on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Finally, Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $90.64.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $64.08 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20. The stock has a market capitalization of $11.12 billion, a P/E ratio of 7.22, a P/E/G ratio of 1.08 and a beta of 0.40. The business has a 50-day moving average price of $74.00 and a two-hundred day moving average price of $75.72.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.07. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities analysts predict that Solventum will post 6.58 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.05% of the company’s stock.

Hedge Funds Weigh In On Solventum

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP grew its stake in Solventum by 19.0% in the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the period. State Street Corp increased its holdings in shares of Solventum by 2.0% in the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after acquiring an additional 124,490 shares in the last quarter. Davis Selected Advisers raised its position in shares of Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares during the period. Finally, Boston Partners raised its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.